Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Investor Presentation (May 2021)
26 slides from Botanix Pharmaceuticals's investor presentation, May 5, 2021
Slide 1: Updated investor presentation and conference call
5 May 2021 Updated investor presentation and conference call For personal use only Philadelphia PA and Perth Australia, 5 May 2021: Clinical dermatology and antimicrobial company, Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”), is pleased to release an updated investor present
Slide 2: Contact details and forward-looking statements
diseases, which it utilises in its existing development programs and is being explored with a number of other product opportunities. The Company is developing a pipeline of product candidates with recent positive data from its BTX 1801 Phase 2a antimicrobial study and plans for an upcoming Phase 2b
Slide 3: Investor Presentation May 2021
For personal use only Investor Presentation May 2021 www.botanixpharma.com
Slide 4: Botanix: leader in topical drug development
Botanix: leader in topical drug development For personal use only Pharmaceutical focus Leveraging novel skin delivery technology (Permetrex™) and novel drug mechanisms of action, including cannabidiol (CBD) Topically driven Targeting key dermatology and antimicrobial indications with topical treatme
Slide 5: Corporate overview
Corporate Corporate overview For personal use only Trading information Share price performance (last 12 months) Share Price ( 4 May 2021) A$0.084 Price (A$) Volume (m) 52 week low / high A$0.037 / A$0.190 $0.20 90 Shares outstanding 973,142,074 80 Market capitalisation A$80.8 $0.16 70 Cash (31 March
Slide 6: World class team
World class team World-class team For personal use only Board of Directors Vince Ippolito Matt Callahan Dr Bill Bosch Dr Stewart Washer President and Executive Chairman Executive Director Executive Director Director COO of Anacor and Medicis with 17 Serial founder and ex-investment 20+ years e
Slide 7: Advanced pipeline
Pharmaceutical focus Advanced pipeline For personal use only Ph 1 Ph 1b Ph 2 Ph 3 Status Positive Phase 2a results 1Q BTX 1801 2021, Phase 2b planned for Antimicrobial 4Q 2021 BTX 1702 First patients enrolled 2Q Rosacea 2021 BTX 1503 Planning underway for Phase 3 Acne clinical studies Actively asses
Slide 8: Permetrex: unique skin delivery technology fuels pipeline
Topically driven PermetrexTM: unique skin delivery technology fuels pipeline Delivers high doses of drug into the layers of the skin without using permeation enhancers, For personal use only preservatives, or irritating levels of alcohol / petroleum derivatives Initial application Evaporation of sol
Slide 9: Independent comparative analysis of CBD delivered
Topically driven Independent comparative analysis of CBD delivered For personal use only Amount of CBD permeated through skin (time elapsed 48 hours) 1 60 Delivered dose in mg/cm2 50 40 ~5x more than closest 30 comparator product ~3x more than closest 20 comparator product 10 - Epidermis Dermis BTX
Slide 10: Our products target markets with significant annual revenue
Significant markets Our products target markets with significant annual revenue For personal use only Antimicrobial Specialised / Rosacea 100k patients Dermatologists 16M patients $0.5bn sales2 $1.9bn sales1 US Prescriber Acne Base 50M patients $5.1bn sales3 General Practitioners Preclinical Phase 1
Slide 11: Synthetic cannabinoids are well suited to treat skin diseases and infections
Pharmaceutical focused Synthetic cannabinoids are well suited to treat skin diseases and infections For personal use only Botanix’s studies show synthetic CBD to:1 Be safe and well tolerated Have broad anti-inflammatory properties Have a strong and consistent impact on lesions Kill Staph aur
Slide 12: BTX 1801 development update
BTX 1801 development update For personal use only
Slide 13: Antimicrobial resistance is a fast-growing problem
Antimicrobial Antimicrobial resistance is a fast-growing problem, with no innovation in over three decades For personal use only Global forecast deaths by 20501 (p.a.) Number of antibiotic classes discovered or patented2 10.0m 9 55+ year gap Without new innovative solutions, No new approved classes
Slide 14: BTX 1801 has remarkable activity against bacteria without inducing resistance
Antimicrobial BTX 1801 has remarkable activity against bacteria without inducing resistance For personal use only MIC daily variability1 12 26x fold increase from Day 1 8 An increase in MIC over time MIC (µg/mL) shows MRSA can develop resistance to the drug 4 1.5x fold increase from Day 1 - 1 2 3 4
Slide 15: BTX 1801 Phase 2a study: clinical efficacy demonstrated
Antimicrobial BTX 1801 Phase 2a study: clinical efficacy demonstrated For personal use only Safe and generally well tolerated at doses of active drug up to 20% All 66 participants successfully Safety & completed the BTX 1801 study tolerability No severe adverse events reported1 BTX 1801 BTX 18
Slide 16: Phase 2a study data: Staph aureus eradication
Antimicrobial Phase 2a study data: Staph aureus eradication For personal use only BTX 1801: Staph aureus eradication rates (% of participants)1 Study observations 80% Significant eradication of Staph aureus 2 days after 5 day 76.2% treatment 68.8% 1 completion of treatment period period Large di
Slide 17: Haemodialysis patients with central venous catheters at risk of bloodstream infections
Antimicrobial Haemodialysis patients with central venous catheters at risk of bloodstream infections For personal use only Haemodialysis Replicates the functions of the kidneys in patients with kidney failure, by using a machine to filter and clean the blood Frequent use of catheters or insertin
Slide 18: Health system impact of haemodialysis infections
Antimicrobial Health system impact of haemodialysis infections For personal use only Patients ~60% ~US$32k US$1bn of Staph aureus–related Mean cost (per episode) of Estimated annual cost of hospital admissions occur treating Staph aureus blood treating bacteraemia in within the first year of the str
Slide 19: BTX 1801: rapid clinical development
Antimicrobial BTX 1801: rapid clinical development For personal use only FDA incentives provide accelerated Next Study Phase 1 Phase 2b development and increase exclusivity Safe and delivers Effective at killing Staph aureus synthetic cannabidiol over 3 months, with three times Extra 5 years (tota
Slide 20: Dermatology clinical programs
Dermatology clinical programs For personal use only
Slide 21: BTX 1702: impact of rosacea and significant market opportunity
Dermatology BTX 1702: impact of rosacea and significant market opportunity For personal use only Papulopustular rosacea is a A rapidly growing market: chronic skin disease Rosacea market projected to grow to US$2.6bn by 20253 characterised by redness (inflammation) and acne- US$2.6bn Anticipated t
Slide 22: BTX 1702: Phase 1b rosacea study start
Dermatology BTX 1702: Phase 1b rosacea study start For personal use only Study design Four dose groups, ~120 patients: Endpoints: – BTX 1702 high dose - twice daily: 40 patients – Safety and tolerability – BTX 1702 low dose - twice daily: 40 patients – Change in inflammatory lesion counts from b
Slide 23: BTX 1503: Successful End-of-Phase FDA Meeting and preparation for Phase 3
Dermatology BTX 1503: Successful End-of-Phase 2 FDA Meeting and preparation for Phase 3 For personal use only Study update Sizable acne prescription market End of Phase 2 meeting with FDA successfully completed FDA highlighted excellent safety profile of BTX 1503, and 22m total prescriptions in
Slide 24: Executing on key clinical milestones
Corporate Executing on key clinical milestones For personal use only Antimicrobial: positive BTX 1801 Phase 2a study results Positive results announced and Phase 2b planned start 4Q 2021 Rosacea: BTX 1702 Phase 1b study start Recruitment currently underway Acne: BTX 1503 planning for Phase 3 c
Slide 25: Disclaimer
DISCLAIMER For personal use only Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate, ”expect,” “intend,” “may,” “plan,” “predict,”
Slide 26: General enquiries
For personal use only General enquiries Botanix Pharmaceuticals Corporate communications +61 8 6555 2945 investors@botanixpharma.com www.botanixpharma.com
Botanix Pharmaceuticals — Investor Presentation (May 2021) on 6ix